Evidence map›Paper›PMID 26285866›Full record

ArticleBMC medical genetics2015

Complete APTX deletion in a patient with ataxia with oculomotor apraxia type 1.

Rick van Minkelen, Miriam Guitart, Conxita Escofet, Grace Yoon, Peter Elfferich, Galhana M Bolman, Robert van der Helm, Raoul van de Graaf, Ans M W van den Ouweland

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC medical genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Rick van MinkelenDepartment of Clinical Genetics, Erasmus Medical Center, P.O. Box 2040, Rotterdam, 3000 CA, The Netherlands. r.vanminkelen@erasmusmc.nl.
Miriam GuitartGenetic Laboratory, UDIAT-Centre Diagnòstic, Neuropediatrics Unity, Corporació Sanitària Universitària Parc Taulí, Sabadell, Spain. MGuitart@tauli.cat.
Conxita EscofetGenetic Laboratory, UDIAT-Centre Diagnòstic, Neuropediatrics Unity, Corporació Sanitària Universitària Parc Taulí, Sabadell, Spain. CEscofet@tauli.cat.
Grace YoonDivision of Clinical and Metabolic Genetics, Department of Pediatrics, The Hospital for Sick Children and University of Toronto, Toronto, Canada. grace.yoon@utoronto.ca.
Peter ElfferichDepartment of Clinical Genetics, Erasmus Medical Center, P.O. Box 2040, Rotterdam, 3000 CA, The Netherlands. p.elfferich@erasmusmc.nl.
Galhana M BolmanDepartment of Clinical Genetics, Erasmus Medical Center, P.O. Box 2040, Rotterdam, 3000 CA, The Netherlands. g.bolman@erasmusmc.nl.
Robert van der HelmDepartment of Clinical Genetics, Erasmus Medical Center, P.O. Box 2040, Rotterdam, 3000 CA, The Netherlands. r.vanderhelm@erasmusmc.nl.
Raoul van de GraafDepartment of Clinical Genetics, Erasmus Medical Center, P.O. Box 2040, Rotterdam, 3000 CA, The Netherlands. r.vandegraaf@erasmusmc.nl.
Ans M W van den OuwelandDepartment of Clinical Genetics, Erasmus Medical Center, P.O. Box 2040, Rotterdam, 3000 CA, The Netherlands. a.vandenouweland@erasmusmc.nl.
Erasmus University Rotterdam · NLCorporació Sanitària Parc Taulí · ESSickKids Foundation · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAtaxia with oculomotor apraxia type 1 is an autosomal-recessive neurodegenerative disorder characterized by a childhood onset of slowly progressive cerebellar ataxia, followed by oculomotor apraxia and a severe primary motor peripheral axonal motor neuropathy. Ataxia with oculomotor apraxia type 1 is caused by bi-allelic mutations in APTX (chromosome 9p21.1). CASE PRESENTATION: Our patient has a clinical presentation that is typical for ataxia with oculomotor apraxia type 1 with no particularly severe phenotype. Multiplex Ligation-dependent Probe Amplification analysis resulted in the identification of a homozygous deletion of all coding APTX exons (3 to 9). SNP array analysis using the Illumina Infinium CytoSNP-850 K microarray indicated that the deletion was about 62 kb. Based on the SNP array results, the breakpoints were found using direct sequence analysis: c.-5 + 1225_*44991del67512, p.0?. Both parents were heterozygous for the deletion. Homozygous complete APTX deletions have been described in literature for two other patients. We obtained a sample from one of these two patients and characterized the deletion (156 kb) as c.-23729_*115366del155489, p.0?, including the non-coding exons 1A and 2 of APTX. The more severe phenotype reported for this patient is not observed in our patient. It remains unclear whether the larger size of the deletion (156 kb vs 62 kb) plays a role in the phenotype (no extra genes are deleted).

conclusionHere we described an ataxia with oculomotor apraxia type 1 patient who has a homozygous deletion of the complete coding region of APTX. In contrast to the patient with the large deletion, our patient does not have a severe phenotype. More patients with deletions of APTX are required to investigate a genotype-phenotype effect.

Indexed as

PhenotypeBase SequenceDNA-Binding ProteinsElectromyographyGene DeletionHumansMaleMicroarray AnalysisMolecular Sequence DataMoroccoNuclear ProteinsPolymorphism, Single NucleotideSequence Analysis, DNASpinocerebellar AtaxiasSpinocerebellar DegenerationsAPTX protein, humanDNA-Binding ProteinsNuclear Proteins

Identifiers

PMID26285866
PMCPMC4593195
OpenAlexW1937586890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.